Abstract: Compounds useful as antiviral agents against DNA-containing viruses, such as herpes group viruses, are disclosed. The compounds are represented by Formula 1.0: ##STR1## and their pharmaceutically acceptable salts and solvates; wherein:(A) X is selected from the group consisting of N--R.sup.3, O, S, and C(R.sup.3).sub.2 ;(B) R.sup.3 is selected from H and a range of substituents;(C) R.sup.1 is an etherifying or esterifying group;(D) R.sup.2 is selected from a range of substituents;(E) m is 0 or an integer from 1 to 4; and(F) R.sup.4 and R.sup.5 are the same and are selected from alkyl and acyl groups;together with the pharmaceutically acceptable salts of the compounds of Formula 1.0 that are acidic or basic.Pharmaceutical compositions containing compounds represented by Formula 1.0 are disclosed. Also disclosed are methods of treating a viral infection using compounds represented by Formula 1.0.

Abstract: Compounds useful as antiviral agents against DNA-containing viruses, such as herpes group viruses, are disclosed. The compounds are are represented by compounds of Formula 1.0: ##STR1## and their pharmaceutically acceptable salts and solvates. Pharmaceutical compositions containing compounds represented by Formula 1.0 and methods of treating a viral infection using compounds represented by Formula 1.0 are disclosed.Also disclosed are compounds useful as antihypertensive agents and methods of treating hypertension using such compounds. The antihypertensive agents are compounds represented by Formula 1.0 wherein R.sup.4 is selected from the group consisting of alkyl and aminoalkyl. Preferably R.sup.1 is H.

Abstract: Aqueous formulations of an interferon, a granulocyte-macrophage colony-stimulating factor or an interleukin are made to have extended storage lifetimes by incorporating methionine, histidine or mixtures thereof.

Abstract: Compounds of the formula ##STR1## wherein R.sub.3, R.sub.4, J, K, Z, and Het are as set forth herein are described.The compounds of formula I are useful as agents in the treatment of fungal infections.

Abstract: A removable, three quarters length, innersole for an article of footwear, adapted to provide cushioning and/or support to a foot. Said innersole comprises a forward toe portion having a radius edge, a rear heel portion having a radius edge and an intermediate arch cushion portion between said toe and heel portions. The forward toe portion, the rear heel portion and said intermediate arch cushion portion are one-piece. The innersole being resilient. The innersole including a first flat bottom surface, a second upper surface having an intermediate arch portion whose contour is generally convex-shaped and a third concave-shaped surface extending from said bottom surface to said upper surface to define with said upper surface an arched projection extending upwardly from said bottom surface and outwardly at a distance about equal to or greater than the tangent of said toe radius edge and said heel radius edge. The arched projection defining a space beneath said third surface.

Abstract: A powder dispenser assembly includes a container for holding a supply of powdered material, the container including a conduit extending therethrough; a metering plate rotatably mounted with respect to the container beneath the supply of powdered material for supplying the powdered material to the conduit, the metering plate including perforated areas therein, each adapted to hold one metered amount of the powdered material, and a first set of ratchet teeth; a blade assembly for scraping the powdered material into the perforated areas, the blade assembly being positioned between the supply of powdered material and the metering plate; a mouthpiece for enabling inhalation of the metered amount of powdered material from one selected perforated area through the conduit; a base rotatably mounted with the container; a spring plate for biasing the metering plate into biased contact with the blade assembly, the spring plate being non-rotatably mounted in the base and including a second set of ratchet teeth for engagin

Abstract: Compounds of the formula ##STR1## or pharmaceutically acceptable salts thereof wherein R.sub.3, R.sub.4, R.sub.7, J, K, Z and Het are as set forth herein are described.The compounds of formula I are useful as agents in the treatment of fungal infections.

Abstract: An adhesive bilayer transdermal dosage system capable of sustained release of a pharmaceutically active drug to the skin of a human patient having a first component layer which is a pharmaceutically active drug-containing essentially planar sheet of an at least partially cross-linked acrylic adhesive. The planar sheet is formed of a flexible self-supporting cross-linked acrylate of sufficient adhesivity, durability and strength whereby intimate diffusional contact with the skin of the patient is maintained for a period of at least about 24 hours without destruction of the physical integrity of the sheet. The sheet is capable of retaining, dispersed therein, sufficient pharmaceutically active drug to deliver to the skin a pharmaceutically effective amount of the drug over a 24-hour period without dissolution of the at least partially crosss-linked acrylic adhesive. The system also contains a second component layer intimately adhered to one side of the first component layer.

Abstract: Compounds of the formula ##STR1## or a pharmaceutically acceptable salt thereof wherein, R is H, halogen, (C.sub.1 -C.sub.6) alkyl, N(C.sub.1 -C.sub.6 alkyl/aryl).sub.2, OH, O--(C.sub.1 -C.sub.6) alkyl/aryl, CH.sub.2 OH, COOH, COO-alkyl/aryl, SO.sub.2 NH.sub.2, or SO.sub.2 NH (C.sub.1 -C.sub.6 alkyl/aryl);R.sub.1 is C.sub.1 -C.sub.6 alkyl, cycloalkyl, C.sub.2 -C.sub.6 alkenyl, heteroaryl, substituted heteroaryl, heterocycloalkyl, --CH.sub.2 -aryl, --CH.sub.2 -substituted aryl, --CH.sub.2 -heteroaryl, or --CH.sub.2 -substituted heteroaryl;R.sub.2 is H, C.sub.1 -C.sub.6 alkyl or aryl; ##STR2## is an aromatic ring or a heteroaromatic ring; and X is O or N-(alkyl/aryl/alkyl-aryl/alkoxylalkoxyaryl)are described. These compounds are useful as agents for treating viruses.

Abstract: A controlled release solid dosage tablet of flutamide is disclosed that is designed to provide an immediate release dose and a second delayed dose in pulsatile manner in the gastrointestinal tract for twice a day use.